Contact
![Contact Meredith Alda](https://cdn.statcdn.com/contactPerson/3646.jpg)
Mon - Fri, 9am - 6pm (EST)
![Contact Yolanda Mega](https://cdn.statcdn.com/contactPerson/3195.jpg)
Mon - Fri, 9am - 5pm (SGT)
![Contact Kisara Mizuno](https://cdn.statcdn.com/contactPerson/2661.jpg)
Mon - Fri, 10:00am - 6:00pm (JST)
![Contact Lodovica Biagi](https://cdn.statcdn.com/contactPerson/863.jpg)
Mon - Fri, 9:30am - 5pm (GMT)
![Contact Carolina Dulin](https://cdn.statcdn.com/contactPerson/3012.jpg)
Mon - Fri, 9am - 6pm (EST)
Key regions: Australia, Italy, France, South Korea, Brazil
The demand for vaccines in Kyrgyzstan has been on the rise in recent years.
Customer preferences: Kyrgyzstan has a population of over 6 million people, and the majority of them prefer vaccines that are affordable and effective. The government has been working to provide free vaccines to its citizens, but there is still a demand for private vaccines that offer additional protection.
Trends in the market: One of the trends in the vaccines market in Kyrgyzstan is the increase in demand for vaccines that protect against infectious diseases. This is due to the rise in the number of cases of infectious diseases in the country. Additionally, there has been an increase in the demand for vaccines that protect against non-communicable diseases, such as cancer and diabetes.
Local special circumstances: Kyrgyzstan is a landlocked country located in Central Asia, and it has a high risk of infectious diseases due to its proximity to other countries with high rates of infectious diseases. The country has a weak healthcare system, which has led to a lack of access to healthcare services in some areas. Additionally, there is a lack of public awareness about the importance of vaccines, which has contributed to the low vaccination rates in the country.
Underlying macroeconomic factors: The Kyrgyz economy is heavily dependent on agriculture and remittances from migrant workers. The country has a low GDP per capita, which has limited the government's ability to invest in healthcare infrastructure and services. The government has been working to improve the healthcare system, but progress has been slow due to limited resources. The country has also been affected by political instability, which has further hindered its economic development.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)